Halozyme picks a new CFO; Retrophin gets on the FDA fast track;

@FierceBiotech: FDA says Sanofi and Regeneron's cardio contender looks approvable. But for whom? More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Vertex beefs up its cystic fibrosis pipeline with $1.2B Parion R&D pact. Article | Follow @JohnCFierce

@DamianFierce: Next week's PCSK9 adcomms are at the "Hilton Washington DC/Gaithersburg," which is like saying "Marriott U.S./Greenland." | Follow @DamianFierce

> Halozyme ($HALO) CFO David Ramsey is retiring later this summer, to be replaced by former Shire ($SHGP) and Amgen ($AMGN) executive Laurie Stelzer. News

> Retrophin ($RTRX) picked up the FDA's fast-track designation for RE-024, a drug in development for the rare pantothenate kinase-associated neurodegeneration, or PKAN. With the nod, the agency promises to cut months off of RE-024 review time once it's submitted. More

Medical Device News

@FierceMedDev: Exact Sciences joins forces with MD Anderson for lung cancer Dx development. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: Journalists who were jailed by the feds call for federal shield law | National Press Club. More | Follow @VarunSaxena2

@EmilyWFierce: OPKO scoops up Bio-Reference Laboratories for $1.47B. News | Follow @EmilyWFierce

> China's Mindray Medical weighing offer from management to take company private. Story

> Medtronic aims for diabetic consumer tech in deals with Samsung, Glooko and connected MiniMed clearance. Article

Pharma News

@FiercePharma: FDA launches safety investigation of controversial raw foods for pets. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA warning letter says Czech company shipped bacteria contaminated APIs to the U.S. More | Follow @EricPFierce

@CarlyHFierce: AbbVie, J&J gallop toward first-line Imbruvica sales with new survival data. FiercePharma report | Follow @CarlyHFierce

> AstraZeneca takes its emerging markets push to Algeria with $125M expansion. Story

> NICE sings a different tune for Bayer's prostate cancer drug Xofigo. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.